Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort study
Abstract Background Autosomal-dominant polycystic kidney disease (ADPKD) is the most prevalent hereditary kidney disease and the fourth leading cause of end-stage renal disease (ESRD) requiring renal replacement therapy (RRT). Nevertheless, there is a paucity of epidemiological research examining th...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-11-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-023-03382-0 |
| _version_ | 1797630383364243456 |
|---|---|
| author | Li-Chi Chen Yi-Chi Chu Tzongshi Lu Hugo Y.-H. Lin Ta-Chien Chan |
| author_facet | Li-Chi Chen Yi-Chi Chu Tzongshi Lu Hugo Y.-H. Lin Ta-Chien Chan |
| author_sort | Li-Chi Chen |
| collection | DOAJ |
| description | Abstract Background Autosomal-dominant polycystic kidney disease (ADPKD) is the most prevalent hereditary kidney disease and the fourth leading cause of end-stage renal disease (ESRD) requiring renal replacement therapy (RRT). Nevertheless, there is a paucity of epidemiological research examining the risk factors and survival on RRT for ADPKD. Thus, we aimed to investigate the cumulative effects of cardiometabolic comorbidities, including hypertension (HTN), type 2 diabetes mellitus (DM), and dyslipidemia (DLP) to clinical outcomes in ADPKD. Methods We identified 6,142 patients with ADPKD aged ≥ 20 years from 2000 to 2015 using a nationwide population-based database. HTN, DM, and DLP diagnoses before or at the time of ADPKD diagnosis and different combinations of the three diagnoses were used as the predictors for the outcomes. Survival analyses were used to estimate the adjusted mortality risk from cardiometabolic comorbidities and the risk for renal survival. Results Patients with ADPKD who developed ESRD had the higher all-cause mortality (HR, 5.14; [95% CI: 3.88–6.80]). Patients with all three of the diseases had a significantly higher risk of entering ESRD (HR:4.15, [95% CI:3.27–5.27]), followed by those with HTN and DM (HR:3.62, [95% CI:2.82–4.65]), HTN and DLP (HR:3.54, [95% CI:2.91–4.31]), and HTN alone (HR:3.10, [95% CI:2.62–3.66]) compared with those without any three cardiometabolic comorbidities. Conclusions Our study discovered the cumulative effect of HTN, DM, and DLP on the risk of developing ESRD, which reinforces the urgency of proactive prevention of cardiometabolic comorbidities to improve renal outcomes and overall survival in ADPKD patients. |
| first_indexed | 2024-03-11T11:06:33Z |
| format | Article |
| id | doaj.art-6c90242cb7bd4f0ba31d5102ba2c0ada |
| institution | Directory Open Access Journal |
| issn | 1471-2369 |
| language | English |
| last_indexed | 2024-03-11T11:06:33Z |
| publishDate | 2023-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj.art-6c90242cb7bd4f0ba31d5102ba2c0ada2023-11-12T12:09:45ZengBMCBMC Nephrology1471-23692023-11-0124111110.1186/s12882-023-03382-0Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort studyLi-Chi Chen0Yi-Chi Chu1Tzongshi Lu2Hugo Y.-H. Lin3Ta-Chien Chan4Research Center for Humanities and Social Sciences, Academia SinicaResearch Center for Humanities and Social Sciences, Academia SinicaRenal Division, Brigham and Women’s Hospital, Harvard Medical SchoolDepartment of Internal Medicine, Kaohsiung Municipal Ta-Tung HospitalResearch Center for Humanities and Social Sciences, Academia SinicaAbstract Background Autosomal-dominant polycystic kidney disease (ADPKD) is the most prevalent hereditary kidney disease and the fourth leading cause of end-stage renal disease (ESRD) requiring renal replacement therapy (RRT). Nevertheless, there is a paucity of epidemiological research examining the risk factors and survival on RRT for ADPKD. Thus, we aimed to investigate the cumulative effects of cardiometabolic comorbidities, including hypertension (HTN), type 2 diabetes mellitus (DM), and dyslipidemia (DLP) to clinical outcomes in ADPKD. Methods We identified 6,142 patients with ADPKD aged ≥ 20 years from 2000 to 2015 using a nationwide population-based database. HTN, DM, and DLP diagnoses before or at the time of ADPKD diagnosis and different combinations of the three diagnoses were used as the predictors for the outcomes. Survival analyses were used to estimate the adjusted mortality risk from cardiometabolic comorbidities and the risk for renal survival. Results Patients with ADPKD who developed ESRD had the higher all-cause mortality (HR, 5.14; [95% CI: 3.88–6.80]). Patients with all three of the diseases had a significantly higher risk of entering ESRD (HR:4.15, [95% CI:3.27–5.27]), followed by those with HTN and DM (HR:3.62, [95% CI:2.82–4.65]), HTN and DLP (HR:3.54, [95% CI:2.91–4.31]), and HTN alone (HR:3.10, [95% CI:2.62–3.66]) compared with those without any three cardiometabolic comorbidities. Conclusions Our study discovered the cumulative effect of HTN, DM, and DLP on the risk of developing ESRD, which reinforces the urgency of proactive prevention of cardiometabolic comorbidities to improve renal outcomes and overall survival in ADPKD patients.https://doi.org/10.1186/s12882-023-03382-0ADPKDCardiometabolic comorbiditiesESRDRenal replacement therapyAll-cause mortality |
| spellingShingle | Li-Chi Chen Yi-Chi Chu Tzongshi Lu Hugo Y.-H. Lin Ta-Chien Chan Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort study BMC Nephrology ADPKD Cardiometabolic comorbidities ESRD Renal replacement therapy All-cause mortality |
| title | Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort study |
| title_full | Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort study |
| title_fullStr | Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort study |
| title_full_unstemmed | Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort study |
| title_short | Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort study |
| title_sort | cardiometabolic comorbidities in autosomal dominant polycystic kidney disease a 16 year retrospective cohort study |
| topic | ADPKD Cardiometabolic comorbidities ESRD Renal replacement therapy All-cause mortality |
| url | https://doi.org/10.1186/s12882-023-03382-0 |
| work_keys_str_mv | AT lichichen cardiometaboliccomorbiditiesinautosomaldominantpolycystickidneydiseasea16yearretrospectivecohortstudy AT yichichu cardiometaboliccomorbiditiesinautosomaldominantpolycystickidneydiseasea16yearretrospectivecohortstudy AT tzongshilu cardiometaboliccomorbiditiesinautosomaldominantpolycystickidneydiseasea16yearretrospectivecohortstudy AT hugoyhlin cardiometaboliccomorbiditiesinautosomaldominantpolycystickidneydiseasea16yearretrospectivecohortstudy AT tachienchan cardiometaboliccomorbiditiesinautosomaldominantpolycystickidneydiseasea16yearretrospectivecohortstudy |